BackGalectin Therapeutics Overview
Galectin Therapeutics Inc

Galectin Therapeutics Return on Equity

Latest ROE for Galectin Therapeutics: 20.35% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

20.35%

Return on Equity

20.35%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Galectin Therapeutics (GALT) FAQ

As of the most recent data, GALT shows a ROE of 20.35%. That is above the Healthcare sector average of 13.1%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about 13.1%. Galectin Therapeutics is at 20.35%, which is higher that average. That is roughly 55.3% above the sector mean. Use the comparison chart on this page to see how GALT stacks up against individual peers as well.

Check the historical chart to see whether GALT's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Galectin Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Galectin Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 20.35%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about 13.1%, while GALT is at 20.35%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.